Global Insights Local Impact
A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai, India. Synopsis Dilip Shanghvi’s Sun Pharma made a bold move entering the specialty-drugs business which has started to pay it back. Now, the company is scouting acquisitions and augmenting its in-house R&D to enhance its specialty-drugs
Read More
Synopsis Phages — microscopic viruses that infect bacteria — were discovered over a 100 years ago, and a small band of scientists quickly realised their potential. However, within a few decades of discovery, they were largely abandoned in favour of antibiotics. But as antibiotics increasingly fail us, and the threat of antimicrobial resistance looms large,
Read More
Synopsis A recent study found that 101 million Indians are living with diabetes. From 70 million just four years ago, that’s a jump of over 40%. What’s worse, another 136 million are on the brink of getting the disease. The economic impact of managing a chronically sick population can seriously hobble India’s demographic edge as
Read More
Healthtech company PharmEasy seems to finally be able to hold its head above water. The unicorn, which has been struggling with slowing growth, debt burden, and steep valuation cuts by investors, had something to cheer about when it turned Ebitda (earnings before interest, taxes, depreciation and amortisation) profitable in April this year. For venture capital
Read More
Himanshu Gadgil, CEO, Enzene Biosciences; Enzene Biosciences in Pune; image credit: Enzene Synopsis Anti-cancer drugs are beyond the reach of average Indian patients. Early-stage patients spend up to INR6 lakh on medicines alone. For advanced stages, the cost is higher. Scientist Himanshu Gadgil gave up a cushy job in the US and returned to India
Read More
Lars Fruergaard Jorgensen, global CEO, Novo Nordisk; image credit: Company Synopsis Lars Fruergaard Jørgensen, the CEO of Novo Nordisk, the world’s largest producer of insulins, shares his thoughts on how to arrest the growing numbers of diabetes patients; the company’s blockbuster weight-loss drug Wegovy; regulating medicine prices; and more. For Lars Fruergaard Jørgensen, CEO, Novo
Read More
By Jessica Hamzelou The baby baboon is wearing a mesh gown and appears to be sitting upright. “This little lady … looks pretty philosophical, I would say,” says Eli Katz, who is showing me the image over a Zoom call. This baboon is the first to receive a heart transplant from a young gene-edited pig
Read More
Nikhil Chopra, CEO, JB Chemicals and Pharmaceuticals Ltd. Image credit: Special Arrangement Synopsis When PE firm KKR took control of JB Pharma in 2020, it was struggling for growth. Competitors had cornered the four legacy brands on which the company relied. Then, Nikhil Chopra, a seasoned hand from Cipla, took over. JB Pharma’s subsequent turnaround
Read More
Friends, I represent the Third World. I represent the needs and aspirations of the Third World. I represent the capabilities of the Third World. And above all, I represent an opportunity…. We all have a responsibility to alleviate the suffering of millions of our fellowmen who are afflicted with HIV and AIDS…. Yusuf Hamied, chairman,
Read More
YK Hamied, non-executive chairman, Cipla Synopsis Cipla may be privately owned, but effectively it has been a ‘national asset’ — with each brick representing Indian ingenuity, enterprise, and strength of character. While shareholders will most likely have no reason to complain, the end losers of Cipla’s founding family’s potential exit will be millions of underprivileged
Read More